AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization (CDSCO) to import for sale and distribution of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin), to be marketed under the brand name Datverzo. This marks the introduction of a new drug in India. Datverzo is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Patients must have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. This approval by the CDSCO enables the marketing of Datopotamab Deruxtecan in India for the specified indication, subject to obtaining any further necessary statutory approvals.